Disruptive innovation – the key to new breakthroughs

Type 1 diabetes is caused by an autoimmune destruction of the insulin-producing pancreatic beta cells. This results in high blood glucose levels, and it is therefore vital that people living with type 1 diabetes receive daily insulin treatment. Based on almost 100 years of experience in discovering and producing treatments for people with diabetes, Novo Nordisk scientists are advancing research to reduce the number of insulin injections required to maintain good glycaemic control, and to prevent low blood glucose (hypoglycaemic) episodes. We are also progressing our research in regenerative medicine such as stem cell therapy, which may one day be used as a curative treatment of type 1 diabetes.

Do you want to know more about living with type 1 diabetes?

“On a personal level, I could not be more motivated.”

After 20 years working in diabetes research, Jacob Sten Petersen, Corporate Vice President and Head of Stem Cell R&D at Novo Nordisk, learned that his daughter Vita has type 1 diabetes. Here he reflects on his very personal motivation to find a cure for the disease, and on the progress of Novo Nordisk’s stem cell research.

Watch Jacob’s story
LinkedIn profile

Type 1 diabetes infographic

Type 1 diabetes infographic

Hypoglycaemia remains a serious unmet need

Hypoglycaemia occurs when the level of glucose in the blood becomes too low. Symptoms include, but are not limited to, sweating, increased heart rate, hunger, dizziness, impaired vision, and even loss of consciousness in severe cases. People with type 1 diabetes are dependent on insulin treatment for survival, but this carries an inherent risk of hypoglycaemia. The psychological burden of patients' anxiety, together with the serious long-term consequences of hypoglycaemia, which include cognitive decline, cardiovascular events and even death, mean that there is a significant need for innovative treatments that offer low or no risk of hypoglycaemia.    


Meet the scientist

“We’re taking little steps every day towards something big.”

Erica Nishimura, Scientific Vice President of Diabetes Research, talks about our common goal of designing an insulin that could one day eliminate hypoglycaemic episodes.

LinkedIn profile

partnering hypo

Towards a future without hypoglycaemia

Novo Nordisk takes part in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.


Learn about Hypo-RESOLVE

Explore partnering opportunities


Guided by the people who know best

At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.

Explore DEEP



Follow our progress

Explore our scientists’ work on new type 1 diabetes treatments.

Recent publications

publications thumbnail

To contribute to the scientific community in our areas of expertise, we take pride in publishing our scientists’ new findings. Visit our library to review some of their recent work.


Explore our publications



A network that changes lives

Clinical trials

Novo Nordisk conducts clinical trials in over 50 countries worldwide, and we have a high retention rate among our trial participants.


Our clinical trials